Group 1 - The company held its ninth meeting of the fifth board of directors on February 11, 2026, with all six directors present, and the meeting was conducted in accordance with relevant regulations [2][3]. - The board approved the termination of the 2025 A-share issuance to specific targets and the withdrawal of the application documents due to changes in the macroeconomic environment and capital market conditions [3][19]. - The decision to terminate the issuance was made after thorough communication and analysis with relevant parties, and the company will continue to monitor capital market dynamics for future financing needs [21][22]. Group 2 - The board also approved the signing of a termination agreement with Shanghai Daoyun Asset Management Co., which was the intended subscriber for the A-share issuance [4][9]. - The termination agreement confirms that there are no disputes or potential disputes between the parties regarding the original subscription agreement, and it will not adversely affect the company's daily operations [13][15]. - The independent directors expressed that the termination of the A-share issuance is a prudent decision that complies with legal regulations and does not harm the interests of shareholders, especially minority shareholders [16][23].

Core Viewpoint - Tianyu Biotechnology Co., Ltd. has decided to terminate the agreement for the issuance of A-shares to specific investors due to changes in the macroeconomic environment and capital market conditions, as well as the company's actual situation [2][21]. Group 1: Termination of Share Issuance - The company held meetings on February 11, 2026, where it approved the termination of the A-share issuance to specific investors and the withdrawal of related application documents [2][24]. - The termination agreement with Shanghai Daoyun Asset Management Co., Ltd. was signed on February 11, 2026, confirming that both parties have no disputes or obligations remaining under the original agreement [6][7]. - The decision to terminate the issuance was made after careful consideration of various factors, including the current economic environment and the company's situation [21][23]. Group 2: Related Party Transactions - Shanghai Daoyun Asset Management Co., Ltd. is controlled by the company's actual controller, Mr. Luo Weiguo, which constitutes a related party transaction [3][4]. - The independent directors have expressed that the termination of the agreement does not harm the interests of the company or its shareholders, particularly minority shareholders [8][23]. - The board of directors approved the termination agreement without the need for further shareholder approval, as authorized by the previous shareholder meeting [9][24]. Group 3: Impact on Company Operations - The termination of the share issuance will not have a significant adverse impact on the company's normal production and operational activities [7][22]. - The company will continue to monitor capital market dynamics and utilize various capital market tools for its long-term development [21].

Core Viewpoint - Tianyu Biotech (603717.SH) has decided to terminate its plan for a specific issuance of A-shares for the year 2025 and will withdraw the related application documents [1] Group 1 - The fifth board meeting of the company will be held on February 11, 2026, to review the decision [1] - The company will apply to the Shanghai Stock Exchange to withdraw the relevant documents regarding the A-share issuance [1]

（记者 张明双） 每经AI快讯，天域生物2月11日晚间发布公告称，天域生物科技股份有限公司于2026年2月11日召开第五 届董事会第九次会议，审议通过了《关于终止公司2025年度向特定对象发行A股股票事项并撤回申请文 件的议案》，公司决定终止2025年度向特定对象发行A股股票事项，并向上海证券交易所申请撤回相关 文件。 每经头条（nbdtoutiao）——男子街头逃亡、剑客山间打斗……电影级中国视频大模型被称"地表最 强"，几十个提示字生成15秒视频可商业交付，影视股大涨！记者亲测 ...

Group 1 - The company Tianyu Biotechnology announced on February 11 that its fifth board meeting was held via telecommunication, where it reviewed the proposal to terminate the issuance of A-shares to specific targets for the fiscal year 2025 and to withdraw the application documents [1] - The decision to withdraw the application indicates a strategic shift in the company's funding approach, potentially impacting its future capital structure and investment plans [1] Group 2 - The news highlights a significant development in the film industry, where a new Chinese video model is generating 15-second videos from dozens of prompts, leading to a surge in stock prices for film-related companies [1] - This advancement in video generation technology is being referred to as the "strongest on earth," suggesting a competitive edge for companies involved in this sector [1]

证券代码：603717 证券简称：天域生物 公告编号：2026-017 天域生物科技股份有限公司 关于与特定对象签署《附条件生效的股份认购协议 之终止协议》暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）于 2025 年 08 月 25 日召 开第四届董事会第六次独立董事专门会议、第四届董事会第四十三次会议，2025 年 09 月 11 日召开 2025 年第三次临时股东大会，分别审议通过了《关于<公司 2025 年度向特定对象发行 A 股股票预案>的议案》《关于公司与特定对象签署< 附条件生效的股份认购协议>暨涉及关联交易的议案》等相关议案，上海导云资 产管理有限公司（以下简称"导云资产"）拟以现金认购公司本次发行的股票， 并与公司签署了《附条件生效的股份认购协议》及《补充协议》。 2026 年 02 月 11 日，公司召开第五届独立董事第三次专门会议、第五届董 事会第九次会议，分别审议通过了《关于终止公司 2025 年度向特定对象发行 A 股股票事项并撤回申请文 ...

证券代码：603717 证券简称：天域生物 公告编号：2026-016 天域生物科技股份有限公司 关于终止 2025 年度向特定对象发行 A 股股票事项 并撤回申请文件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）于 2026 年 02 月 11 日召 开第五届董事会第九次会议，审议通过了《关于终止公司 2025 年度向特定对象 发行 A 股股票事项并撤回申请文件的议案》，公司决定终止 2025 年度向特定对 象发行 A 股股票事项，并向上海证券交易所（以下简称"上交所"）申请撤回 相关文件。现将相关事项公告如下： 一、本次向特定对象发行 A 股股票事项的基本情况 1、2025 年 08 月 25 日，公司召开第四届董事会第四十三次会议，并于 2025 年 09 月 11 日召开 2025 年第三次临时股东大会，审议通过了《关于<公司 2025 年度向特定对象发行 A 股股票预案>的议案》等相关议案，公司编制并披露了 《2025 年度向特定对象发行 A 股股票预案》等。 2 ...

证券代码：603717 证券简称：天域生物 公告编号：2026-015 天域生物科技股份有限公司 第五届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 自公司披露本次向特定对象发行 A 股股票事项以来，公司与相关中介机构 积极推进各项工作。现综合考虑当前宏观经济环境、资本市场环境变化及公司实 际情况等诸多因素，经与相关各方充分沟通、审慎分析后，公司决定终止本次向 特定对象发行 A 股股票事项并撤回申请文件。具体内容详见公司于同日在上海 证券交易所官方网站和指定信息披露媒体上发布的《关于终止 2025 年度向特定 对象发行 A 股股票事项并撤回申请文件的公告》（公告编码：2026-016）。 表决结果：6 票同意、0 票反对、0 票弃权、0 票回避。 1 本议案已经第五届董事会第三次独立董事专门会议事前审议通过。根据公司 2025 年第三次临时股东大会的授权，本议案无需提交股东会审议。 一、董事会会议召开情况 天域生物科技股份有限公司（以下简称"公司"）第五届董事会第九次会议 （以下简称"本次会议"）通 ...

Group 1 - The company, Tianyu Biology (603717.SH), has decided to terminate its plan for a private placement of A-shares due to various factors including the current macroeconomic environment and changes in the capital market [1] - The company has actively communicated with relevant intermediaries and conducted careful analysis before making the decision to withdraw the application [1] - The company will continue to monitor capital market dynamics and will utilize various capital market tools as needed to support its long-term healthy development [1]

天域生物公告称，公司于2026年2月11日召开相关会议，审议通过终止2025年度向特定对象发行A股股 票事项并撤回申请文件，同意与导云资产签署《附条件生效的股份认购协议之终止协议》。导云资产为 公司实控人罗卫国控制的企业，本次签署终止协议构成关联交易，但不构成重大资产重组。该事项经董 事会审议通过，无需提交股东会。目前公司生产经营正常，签署终止协议不会造成重大不利影响。 ...